Used in targeted cancer therapies, particularly in inhibiting tumor growth driven by Wnt signaling pathway activation. It neutralizes RSPO1 (R-spondin 1), a protein that enhances Wnt signaling, which is often overactive in certain cancers such as colorectal and ovarian cancers. By blocking RSPO1, this antibody reduces Wnt pathway activity, suppressing cancer cell proliferation and tumor progression. It has been explored in preclinical and clinical development for solid tumors, especially those with RSPO gene fusions. Also serves as a reference reagent in developing biosimilars and evaluating anti-RSPO1 therapeutic candidates.